OB/GYN and Women's Health - Global Oncology Academy

17-32 of 94

Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Project Oncology®
Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
- Pavani Chalasani, MD, MPH
- Timothy Yap, MBBS, PhD, FRCP
From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
Project Oncology®
From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
- Seth Wander, MD, PhD
Tracking Tumor Resistance in Metastatic Breast Cancer Care
Tracking Tumor Resistance in Metastatic Breast Cancer Care
On the Frontlines of Metastatic Breast Cancer
Tracking Tumor Resistance in Metastatic Breast Cancer Care
- Ryan Quigley
- Megan Kruse, MD
Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
Project Oncology®
Giredestrant and Everolimus in HR+/HER2- Breast Cancer: Insights from evERA
- Pavani Chalasani, MD, MPH
- Erica L. Mayer, MD, MPH
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
Project Oncology®
SERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
- Pavani Chalasani, MD, MPH
- Erica L. Mayer, MD, MPH
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
Project Oncology®
Advancing Endometrial Cancer Care: Molecular Targets and Emerging Therapies
- Casey Cosgrove, MD
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Project Oncology®
Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
- Brian Slomovitz, MD
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Project Oncology®
Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
- Brian Slomovitz, MD
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Project Oncology®
Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
- Ryan Quigley
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
Project Oncology®
Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
- Ryan Quigley
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
Project Oncology®
The Future of Immunotherapy: Advancing Care in Endometrial Cancer
- Casey Cosgrove, MD
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Project Oncology®
Dexamethasone Timing and Infusion Reactions in HER2+ Breast Cancer
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
Project Oncology®
Early Adulthood Weight Gain Linked to Breast Tissue Complexity Changes
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Project Oncology®
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Project Oncology®
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
Project Oncology®
Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
- Pavani Chalasani, MD, MPH
- Antonio Giordano, MD, PhD

2/6